{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-24-000029","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.574761+00:00","generated_at":"2026-05-29T10:54:21.938324+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"PTC Therapeutics signs $1B upfront license deal with Novartis for PTC518 HD program","bullets":["PTC receives $1.0B upfront; eligible for up to $1.9B in development, regulatory and sales milestones.","PTC will receive 40% share of U.S. profits/losses and tiered double-digit royalties on ex-U.S. sales.","Novartis will assume global development, manufacturing and commercialization after placebo-controlled portion of PIVOT-HD trial.","Transaction expected to close in Q1 2025, subject to regulatory clearance and customary conditions.","PTC intends to use proceeds to expand splicing platform and support commercial/development portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-24-000029","json":"https://secwatch.observer/filing/0001070081-24-000029.json","markdown":"https://secwatch.observer/filing/0001070081-24-000029.md","text":"https://secwatch.observer/filing/0001070081-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000029/0001070081-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000029/tmb-20241127x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T10:54:21.938324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}